Bradley A. Warady

Bradley A. Warady

Auto-generated profile, based on publicly available information

Bradley A. Warady

Children’s Mercy Kansas City, Kansas City, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2007 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
BWBradley A. Warady
Bradley A. Warady
VCVimal Chadha
Vimal Chadha
In contrast to the increasing availability of information pertaining to the care of children with chronic kidney disease (CKD) from large-scale observational and interventional studies, epidemiological information on the incidence and prevalence of pediatric CKD is currently limited, imprecise, and flawed by methodological differences between the various data sources. There are distinct geographic differences in the reported causes of CKD in children, in part due to environmental, racial, genetic, and cultural (consanguinity) differences. However, a substantial percentage of children develop CKD early in life, with congenital renal disorders such as obstructive uropathy and aplasia/hypoplasia/dysplasia being responsible for almost one half of all cases. The most favored end-stage renal disease (ESRD) treatment modality in children is renal transplantation, but a lack of health care resources and high patient mortality in the developing world limits the global provision of renal replacement therapy (RRT) and influences patient prevalence. Additional efforts to define the epidemiology of pediatric CKD worldwide are necessary if a better understanding of the full extent of the problem, areas for study, and the potential impact of intervention is desired.

1 June 2015 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
BWBradley A. Warady
Bradley A. Warady
AAAlison G. Abraham
Alison G. Abraham
GSGeorge J. Schwartz
George J. Schwartz
CWCraig S. Wong
Craig S. Wong
AMAlvaro Muñoz
Alvaro Muñoz
SFSusan Furth
Susan Furth

1 June 2012 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Closed access
BWBradley A. Warady
Bradley A. Warady
SBSevcan Bakkaloglu
Sevcan Bakkaloglu
JNJason Newland
Jason Newland
MCMichelle Cantwell
Michelle Cantwell
EVEnrico Eugenio Verrina
Enrico Eugenio Verrina
FSFranz Schaefer
Franz Schaefer

25 September 2012 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
LLL. Li
L. Li
PKP. Khatri
P. Khatri
TST. K. Sigdel
T. K. Sigdel
TTT. Tran
T. Tran
LYL. Ying
L. Ying
MSM. M. Sarwal
M. M. Sarwal
Monitoring of renal graft status through peripheral blood (PB) rather than invasive biopsy is important as it will lessen the risk of infection and other stresses, while reducing the costs of rejection diagnosis. Blood gene biomarker panels were discovered by microarrays at a single center and subsequently validated and cross‐validated by QPCR in the NIH SNSO1 randomized study from 12 US pediatric transplant programs. A total of 367 unique human PB samples, each paired with a graft biopsy for centralized, blinded phenotype classification, were analyzed (115 acute rejection (AR), 180 stable and 72 other causes of graft injury). Of the differentially expressed genes by microarray, Q‐PCR analysis of a five gene‐set (DUSP1, PBEF1, PSEN1, MAPK9 and NKTR) classified AR with high accuracy. A logistic regression model was built on independent training‐set (n = 47) and validated on independent test‐set (n = 198)samples, discriminating AR from STA with 91% sensitivity and 94% specificity and AR from all other non‐AR phenotypes with 91% sensitivity and 90% specificity. The 5‐gene set can diagnose AR potentially avoiding the need for invasive renal biopsy. These data support the conduct of a prospective study to validate the clinical predictive utility of this diagnostic tool.

1 September 2020 in Kidney Medicine
Verified
Journal Article
Open access
BWBradley A. Warady
Bradley A. Warady
RARajiv Agarwal
Rajiv Agarwal
SBSripal Bangalore
Sripal Bangalore
ACArlene Chapman
Arlene Chapman
ALAdeera Levin
Adeera Levin
GCGlenn M. Chertow
Glenn M. Chertow
Alport syndrome affects up to 60,000 people in the United States. The proposed reclassification of thin basement membrane nephropathy and some cases of focal segmental glomerulosclerosis as Alport syndrome could substantially increase the affected population. The reclassification scheme categorizes Alport syndrome as 3 distinct diseases of type IV collagen α3/4/5 based on a genetic evaluation: X-linked, autosomal, and digenic. This approach has the advantage of identifying patients at risk for progressive loss of kidney function. Furthermore, the shared molecular cause of Alport syndrome and thin basement membrane nephropathy arises from mutations in the COL4A3, COL4A4, and COL4A5 genes, which contribute to downstream pathophysiologic consequences, including chronic kidney inflammation. Recent evidence indicates that chronic inflammation and its regulation through anti-inflammatory nuclear factor erythroid 2–related factor 2 (Nrf2) and proinflammatory nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) transcription factors plays a central role in renal tubular and glomerular cell responses to injury. Crosstalk between the Nrf2 and NF-κB pathways is important in the regulation of inflammation in patients with chronic kidney disease; moreover, there is evidence that an insufficient Nrf2 response to inflammation contributes to disease progression. Given the association between type IV collagen abnormalities and chronic inflammation, there is renewed interest in targeted anti-inflammatory therapies in Alport syndrome and other forms of progressive chronic kidney disease.

23 July 2003 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
BWBradley A. Warady
Bradley A. Warady
MHMartin Ho
Martin Ho